http://www.cidrap.umn.edu/cidrap/content/influenza/avianflu/news/jun0706vical.html
Jun 7, 2006 (CIDRAP News) ? Vical Inc., San Diego, announced today it would receive early access to $2.6 million in government funds to help it complete preclinical development of a DNA vaccine for avian influenza.
Last September the National Institute of Allergy and Infectious Diseases (NIAID) awarded the company a $2.9 million challenge grant to develop the vaccine. In May the company reported the vaccine had protected mice and ferrets against a highly virulent strain of H5N1 avian flu virus and had protected mice against multiple human flu strains.
Jun 7, 2006 (CIDRAP News) ? Vical Inc., San Diego, announced today it would receive early access to $2.6 million in government funds to help it complete preclinical development of a DNA vaccine for avian influenza.
Last September the National Institute of Allergy and Infectious Diseases (NIAID) awarded the company a $2.9 million challenge grant to develop the vaccine. In May the company reported the vaccine had protected mice and ferrets against a highly virulent strain of H5N1 avian flu virus and had protected mice against multiple human flu strains.